Jean-Yves Blay

Has grant

University Professor, Medical Oncology

Université Claude Bernard Lyon 1 - Domaine de Rockefeller

France

Research Interests

Explore related searches

Professors in France Professors in Immunology Immunology professors in France

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Jean-Yves Blay is a University Professor of Medical Oncology at Université Claude Bernard Lyon 1 in France. His research focuses on areas including liposarcoma, gastrointestinal stromal tumors, and sarcoma treatments, as evidenced by his recent publications on various clinical studies and treatment outcomes. He is actively involved in evaluating the efficacy and safety of innovative therapies in oncology, contributing significantly to the understanding of cancer management and care standards in the Asia-Pacific region.

Recent Grants

Grant: Close

LYRICAN

Open Date: 2018-01-01

Close Date: 2021-01-01

Grant: Close

EuroSARC

Open Date: 2012-01-01

Close Date: 2016-01-01

Grant: Close

LYRIC

Open Date: 2011-09-01

Close Date: 2016-09-01

Grant: Close

NetSARC

Open Date: 2009-09-01

Close Date: 2014-09-01

Grant: Close

ConticaNET

Open Date: 2006-02-01

Close Date: 2011-02-01

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (15)

François Bertucci

Aix-Marseille University

FRANCE

Jean-Yves Blay

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (20)

Phase I First-in-Human Study of TRK-950, an IgG1 Antibody Specific to CAPRIN-1, in Patients with Advanced Solid Tumors

Imatinib alternating with regorafenib compared to imatinib alone for the first-line treatment of advanced gastrointestinal stromal tumor: The AGITG ALT-GIST intergroup randomized phase II trial

Clinical presentation, management and outcome of 11132 patients with liposarcoma: a population-based study from the NETSARC+ registry

Reply to: Critical evaluation of the ProfiLER-02 study design and outcomes

Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE

Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: final results of the ENLIVEN study

Adjuvant treatment of gastrointestinal stromal tumor: State of the art in 2025

Results of a phase Ib study of olaparib with concomitant radiotherapy in soft-tissue sarcoma: a French sarcoma group study

Twenty year survival of advanced gastrointestinal stromal tumours treated with imatinib Exploratory long-term follow-up of the BFR14 trial

Quality-of-care indicators for oncology management: an analysis of Asia-Pacific healthcare and oncology indicators

Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study.

Efficacy and Safety of Adjuvant Radiotherapy in Re-excised Soft-tissue Sarcoma After Unplanned Resection

Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort

ESR1 Rearrangement as a Diagnostic and Predictive Biomarker in Uterine Tumor Resembling Ovarian Sex Cord Tumor: A Report of Four Cases

Evolution of Patterns of Care and Outcomes in the Real-Life Setting for Patients with Metastatic GIST Treated in Three French Expert Centers over Three Decades

Comprehensive Immune Profiling Unveils a Subset of Leiomyosarcoma with “Hot” Tumor Immune Microenvironment

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond

Controversies in the management of patients with soft tissue sarcoma: Recommendations of the Conference on State of Science in Sarcoma 2022

Distinct Cellular Origins and Differentiation Process Account for Distinct Oncogenic and Clinical Behaviors of Leiomyosarcomas

Collaborators (15)

François Bertucci

Timothy J. Price

isabelle ray coquard

Margaret von Mehren

Philippe A. Cassier

Christophe Le Tourneau

Angelo Paolo Dei Tos

John R. Zalcberg

John Healey

Benoit You

Hans Gelderblom

Anthony Gonçalves

Sebastian Bauer

Maud Kamal

Desmond Yip

Make your next move.